Having worked extensively within the European pharmaceutical industry for almost 30 years,
EU Vigilance provides experienced and dedicated staff with expertise in all phases of
pharmacovigilance (e.g. Modeling, submission support, signal detection, reporting, etc.).
Here you can read a selection of publishes articlesfrom our directors:
DIRECTOR and CEO
Dr. Owen R.W. Lewellen PhD, BSc, C.Chem, FRSC, FTOPRA.
2013: Yves Tillet, Owen Lewellen, Anne-Catherine Maillols-Perroy. When does healthcare stand-alone software become a medical device ? Regulatory Rapporteur Vol 10, No 1
2012: Anne-Catherine Maillols-Perroy, Yves Tillet, Owen Lewellen. The new Medicinal products and Health Products Safety Reform Act in France: reform or storm? Regulatory Rapporteur, Vol 9 No 5.
2009: Owen Lewellen & Paolo Biffignandi. At the forefront of pharmacovigilance - Editorial. Regulatory Rapporteur – Vol 6, No 2.
2009: Interview with June Raine (MHRA). Regulatory Rapporteur – Vol 6, No 2.
2000: Owen Lewellen. A lack of harmonisation in the controls on prescription product promotion - can this continue ? PART 1. ESRA Rapporteur Vol 7, No 1.
2000: Owen Lewellen. A lack of harmonisation in the controls on prescription product promotion - can this continue ? PART 2. ESRA Rapporteur Vol 7, No 2.
DIRECTOR and CHIEF SCIENTIFIC OFFICER
Dr. Axel Wenzel PhD, MSc, BSc, FTOPRA, Lecturing Professor Universities Essen-Duisburg and DUW
DIRECTOR and CHIEF MEDICAL OFFICER
Prof. Dr. Paolo Biffignandi MD, PhD Pharmocology, FTOPRA, FRSM, EU QPPV